Q&A With Chairman and CEO of Aethlon Medical (OTCQB: AEMD) Discussing Launch of New Subsidiary, Exosome Sciences, Inc.
24 sept. 2013 08h30 HE
|
InvestorIdeas.com
POINT ROBERTS, WA and NEW YORK, NY--(Marketwired - Sep 24, 2013) - Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical...
Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
11 sept. 2013 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 11, 2013) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration's...
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
09 sept. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
28 août 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the...
Nuvilex Remains Under Fire While Investors Hold
27 août 2013 10h10 HE
|
Nuvilex, Inc.
SAN DIEGO, CA--(Marketwired - Aug 27, 2013) - The OTC Journal, the longest running electronic newsletter focused on the small cap and microcap sectors, suggests investors consider the agenda when...
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
22 août 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...
Nuvilex, Inc. Strengthens Its Hand in the Cancer Arena With Purchase of Assets
30 juil. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 30, 2013) - Nuvilex, Inc. (OTCQB: NVLX) became a much more valuable company in July when it closed a deal it was fully prepared to pay a great deal more money for,...
Nuvilex, Inc. Moves Closer to Head to Head With Eli Lilly in Phase III Clinical Trials
25 juil. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 25, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly's blockbuster cancer drug, Gemzar, and doing so with the knowledge...
Nuvilex, Inc. Will Enter Phase III Trials With Advantages Using Cell Encapsulation
09 juil. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 9, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) enters its pivotal Phase III clinical trial using its cell encapsulation technology combined with the anti-cancer drug...
Nuvilex, Inc. a Biotech Developing Treatments for Healthcare's Hard Targets
26 juin 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) executives aren't daunted by the statistics. As a matter of fact, they're aware the research they do is directed...